Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode

EMBO Journal

Volumn 35, Issue 10, 2016, Pages 1133-1149

  Forneris, Federico ^a,e   Wu, Jin ^a   Xue, Xiaoguang ^a   Ricklin, Daniel ^b   Lin, Zhuoer ^b   Sfyroera, Georgia ^b   Tzekou, Apostolia ^b   Volokhina, Elena ^c   Granneman, Joke C M ^a   Hauhart, Richard ^d   Bertram, Paula ^d   Liszewski, M Kathryn ^d   Atkinson, John P ^d   Lambris, John D ^b   Gros, Piet ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

cofactor activity; complement; decay accelerating activity; immune evasion; regulators of complement activity

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; REGULATOR PROTEIN; SMALLPOX INHIBITOR OF COMPLEMENT ENZYME; UNCLASSIFIED DRUG; VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN; VIRUS ENZYME; CD46 PROTEIN, HUMAN; CR1 PROTEIN, HUMAN; MATRIX PROTEIN; SPICE PROTEIN, VARIOLA VIRUS;

ARTICLE; BINDING AFFINITY; COMPLEMENT ACTIVATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; HUMAN; HUMAN CELL; MEDIATOR RELEASE; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; BINDING SITE; CHEMISTRY; METABOLISM;

ANTIGENS, CD46; ANTIGENS, CD55; BINDING SITES; COMPLEMENT ACTIVATION; COMPLEMENT C3B; HUMANS; PROTEIN DOMAINS; RECEPTORS, COMPLEMENT 3B; VIRAL MATRIX PROTEINS;

EID: 84961792791     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.15252/embj.201593673     Document Type: Article

References (109)

1. Adams EM, Brown MC, Nunge M, Krych M, Atkinson JP, (1991) Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol 147: 3005-3011
2. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH, (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221
3. Ahmad M, Pyaram K, Mullick J, Sahu A, (2007) Viral complement regulators: the expert mimicking swindlers. Indian J Biochem Biophys 44: 331-343
4. Ahmad M, Raut S, Pyaram K, Kamble A, Mullick J, Sahu A, (2010) Domain swapping reveals complement control protein modules critical for imparting cofactor and decay-accelerating activities in vaccinia virus complement control protein. J Immunol 185: 6128-6137
5. Aleshin AE, DiScipio RG, Stec B, Liddington RC, (2012) Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex. J Biol Chem 287: 19642-19652
6. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA, (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 98: 10037-10041
7. Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG, (2011) iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 67: 271-281
8. Birmingham DJ, Chen W, Liang G, Schmitt HC, Gavit K, Nagaraja HN, (2003) A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b. Immunology 108: 531-538
9. Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, Gros P, (1999) Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 18: 5166-5174
10. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108: 1267-1279
11. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC, (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66: 12-21
12. Ciulla E, Emery A, Konz D, Krushkal J, (2005) Evolutionary history of orthopoxvirus proteins similar to human complement regulators. Gene 355: 40-47
13. Clark SJ, Ridge LA, Herbert AP, Hakobyan S, Mulloy B, Lennon R, Wurzner R, Morgan BP, Uhrin D, Bishop PN, Day AJ, (2013) Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol 190: 2049-2057
14. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763
15. Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB, (2010) Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin Thromb Hemost 36: 633-640
16. Dragon-Durey MA, Fremeaux-Bacchi V, (2005) Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol 27: 359-374
17. Emsley P, Lohkamp B, Scott WG, Cowtan K, (2010) Features and development of Coot. Acta Crystallographica Section D 66: 486-501
18. Forneris F, Ricklin D, Wu J, Tzekou A, Wallace RS, Lambris JD, Gros P, (2010) Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330: 1816-1820
19. Forneris F, Wu J, Gros P, (2012) The modular serine proteases of the complement cascade. Curr Opin Struct Biol 22: 333-341
20. Fredslund F, Jenner L, Husted LB, Nyborg J, Andersen GR, Sottrup-Jensen L, (2006) The structure of bovine complement component 3 reveals the basis for thioester function. J Mol Biol 361: 115-127
21. Fredslund F, Laursen NS, Roversi P, Jenner L, Oliveira CL, Pedersen JS, Nunn MA, Lea SM, Discipio R, Sottrup-Jensen L, Andersen GR, (2008) Structure of and influence of a tick complement inhibitor on human complement component 5. Nat Immunol 9: 753-760
22. Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, et al, (2008) Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948-4952
23. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Loirat C, Atkinson JP, (2006) Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 17: 2017-2025
24. Furtado PB, Huang CY, Ihyembe D, Hammond RA, Marsh HC, Perkins SJ, (2008) The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands. J Mol Biol 375: 102-118
25. Garcia BL, Ramyar KX, Tzekou A, Ricklin D, McWhorter WJ, Lambris JD, Geisbrecht BV, (2010) Molecular Basis for Complement Recognition and Inhibition Determined by Crystallographic Studies of the Staphylococcal Complement Inhibitor (SCIN) Bound to C3c and C3b. J Mol Biol 402: 17-29
26. Gautam AK, Panse Y, Ghosh P, Reza MJ, Mullick J, Sahu A, (2015) Mutational analysis of Kaposica reveals that bridging of MG2 and CUB domains of target protein is crucial for the cofactor activity of RCA proteins. Proc Natl Acad Sci USA 112: 12794-12799
27. Gordon DL, Kaufman RM, Blackmore TK, Kwong J, Lublin DM, (1995) Identification of complement regulatory domains in human factor H. J Immunol 155: 348-356
28. Gropp K, Weber N, Reuter M, Micklisch S, Kopka I, Hallstrom T, Skerka C, (2011) beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood 118: 2774-2783
29. Hadders MA, Bubeck D, Roversi P, Hakobyan S, Forneris F, Morgan BP, Pangburn MK, Llorca O, Lea SM, Gros P, (2012) Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep 1: 200-207
30. Harris CL, Abbott RJ, Smith RA, Morgan BP, Lea SM, (2005) Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J Biol Chem 280: 2569-2578
31. Harris CL, Pettigrew DM, Lea SM, Morgan BP, (2007) Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay. J Immunol 178: 352-359
32. Hebecker M, Alba-Dominguez M, Roumenina LT, Reuter S, Hyvarinen S, Dragon-Durey MA, Jokiranta TS, Sanchez-Corral P, Jozsi M, (2013) An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol 191: 912-921
33. Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, Morgan BP, Harris CL, (2011) Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA 108: 8761-8766
34. Hourcade DE, Mitchell LM, Medof ME, (1999) Decay acceleration of the complement alternative pathway C3 convertase. Immunopharmacology 42: 167-173
35. Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P, (2006) Structure of C3b reveals conformational changes that underlie complement activity. Nature 444: 213-216
36. Janssen BJ, Gomes L, Koning RI, Svergun DI, Koster AJ, Fritzinger DC, Vogel CW, Gros P, (2009) Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J 28: 2469-2478
37. Janssen BJ, Huizinga EG, Raaijmakers HC, Roos A, Daha MR, Nilsson-Ekdahl K, Nilsson B, Gros P, (2005) Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437: 505-511
38. Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S, (2000) Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem 275: 27657-27662
39. Kabsch W, (2010) Xds. Acta Crystallogr D Biol Crystallogr 66: 125-132
40. Kajander T, Lehtinen MJ, Hyvarinen S, Bhattacharjee A, Leung E, Isenman DE, Meri S, Goldman A, Jokiranta TS, (2011) Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci USA 108: 2897-2902
41. Karplus PA, Diederichs K, (2012) Linking crystallographic model and data quality. Science 336: 1030-1033
42. Katschke KJ Jr, Stawicki S, Yin J, Steffek M, Xi H, Sturgeon L, Hass PE, Loyet KM, Deforge L, Wu Y, van Lookeren Campagne M, Wiesmann C, (2009) Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J Biol Chem 284: 10473-10479
43. Kidmose RT, Laursen NS, Dobo J, Kjaer TR, Sirotkina S, Yatime L, Sottrup-Jensen L, Thiel S, Gal P, Andersen GR, (2012) Structural basis for activation of the complement system by component C4 cleavage. Proc Natl Acad Sci USA 109: 15425-15430
44. Kirkitadze MD, Barlow PN, (2001) Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev 180: 146-161
45. Kirkitadze MD, Krych M, Uhrin D, Dryden DT, Smith BO, Cooper A, Wang X, Hauhart R, Atkinson JP, Barlow PN, (1999) Independently melting modules and highly structured intermodular junctions within complement receptor type 1. Biochemistry 38: 7019-7031
46. Krissinel E, Henrick K, (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774-797
47. Krych M, Clemenza L, Howdeshell D, Hauhart R, Hourcade D, Atkinson JP, (1994) Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J Biol Chem 269: 13273-13278
48. Krych M, Hauhart R, Atkinson JP, (1998) Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem 273: 8623-8629
49. Krych M, Hourcade D, Atkinson JP, (1991) Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc Natl Acad Sci USA 88: 4353-4357
50. Krych-Goldberg M, Hauhart RE, Porzukowiak T, Atkinson JP, (2005) Synergy between two active sites of human complement receptor type 1 (CD35) in complement regulation: implications for the structure of the classical pathway C3 convertase and generation of more potent inhibitors. J Immunol 175: 4528-4535
51. Krych-Goldberg M, Hauhart RE, Subramanian VB, Yurcisin BM 2nd, Crimmins DL, Hourcade DE, Atkinson JP, (1999) Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases. J Biol Chem 274: 31160-31168
52. Kuttner-Kondo L, Hourcade DE, Anderson VE, Muqim N, Mitchell L, Soares DC, Barlow PN, Medof ME, (2007) Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases. J Biol Chem 282: 18552-18562
53. Kuttner-Kondo LA, Dybvig MP, Mitchell LM, Muqim N, Atkinson JP, Medof ME, Hourcade DE, (2003) A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases. J Biol Chem 278: 52386-52391
54. Kuttner-Kondo LA, Mitchell L, Hourcade DE, Medof ME, (2001) Characterization of the active sites in decay-accelerating factor. J Immunol 167: 2164-2171
55. Lambris JD, Lao Z, Oglesby TJ, Atkinson JP, Hack CE, Becherer JD, (1996) Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component. J Immunol 156: 4821-4832
56. Liszewski MK, Atkinson JP, (2015a) Complement regulators in human disease: lessons from modern genetics. J Intern Med 277: 294-305
57. Liszewski MK, Atkinson JP, (2015b) Complement regulator CD46: genetic variants and disease associations. Hum Genomics 9: 7
58. Liszewski MK, Leung M, Cui W, Subramanian VB, Parkinson J, Barlow PN, Manchester M, Atkinson JP, (2000) Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem 275: 37692-37701
59. Liszewski MK, Leung MK, Atkinson JP, (1998) Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function. J Immunol 161: 3711-3718
60. Liszewski MK, Leung MK, Hauhart R, Buller RM, Bertram P, Wang X, Rosengard AM, Kotwal GJ, Atkinson JP, (2006) Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol 176: 3725-3734
61. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP, (2009) Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol 183: 3150-3159
62. Lukacik P, Roversi P, White J, Esser D, Smith GP, Billington J, Williams PA, Rudd PM, Wormald MR, Harvey DJ, Crispin MD, Radcliffe CM, Dwek RA, Evans DJ, Morgan BP, Smith RA, Lea SM, (2004) Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc Natl Acad Sci USA 101: 1279-1284
63. Lutteke T, von der Lieth CW, (2004) pdb-care (PDB carbohydrate residue check): a program to support annotation of complex carbohydrate structures in PDB files. BMC Bioinformatics 5: 69
64. Luzzatto L, Gianfaldoni G, (2006) Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria. Int J Hematol 84: 104-112
65. Makou E, Herbert AP, Barlow PN, (2013) Functional anatomy of complement factor H. Biochemistry 52: 3949-3962
66. Marrero A, Duquerroy S, Trapani S, Goulas T, Guevara T, Andersen GR, Navaza J, Sottrup-Jensen L, Gomis-Ruth FX, (2012) The crystal structure of human alpha2-macroglobulin reveals a unique molecular cage. Angew Chem Int Ed Engl 51: 3340-3344
67. Martinez-Barricarte R, Heurich M, Lopez-Perrote A, Tortajada A, Pinto S, Lopez-Trascasa M, Sanchez-Corral P, Morgan BP, Llorca O, Harris CL, Rodriguez de Cordoba S, (2015) The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Mol Immunol 66: 263-273
68. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, Rodriguez de Cordoba S, (2010) Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120: 3702-3712
69. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ, (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674
70. McLure CA, Dawkins RL, Williamson JF, Davies RA, Berry J, Natalie LJ, Laird R, Gaudieri S, (2004) Amino acid patterns within short consensus repeats define conserved duplicons shared by genes of the RCA complex. J Mol Evol 59: 143-157
71. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT, (2015a) Complement System Part I-Molecular Mechanisms of Activation and Regulation. Front Immunol 6: 262
72. Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT, (2015b) Complement System Part II: Role in Immunity. Front Immunol 6: 257
73. Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP, Kavanagh D, Mertens HD, Svergun DI, Johansson CM, Uhrin D, Barlow PN, Hannan JP, (2011) Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol 18: 463-470
74. Mortensen S, Kidmose RT, Petersen SV, Szilagyi A, Prohaszka Z, Andersen GR, (2015) Structural Basis for the Function of Complement Component C4 within the Classical and Lectin Pathways of Complement. J Immunol 194: 5488-5496
75. Nicholson-Weller A, Wang CE, (1994) Structure and function of decay accelerating factor CD55. J Lab Clin Med 123: 485-491
76. Nonaka M, Yoshizaki F, (2004) Primitive complement system of invertebrates. Immunol Rev 198: 203-215
77. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G, (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5: 1844-1859
78. Ojha H, Panwar HS, Gorham RD Jr, Morikis D, Sahu A, (2014) Viral regulators of complement activation: structure, function and evolution. Mol Immunol 61: 89-99
79. Oran AE, Isenman DE, (1999) Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35). J Biol Chem 274: 5120-5130
80. Park HJ, Guariento M, Maciejewski M, Hauhart R, Tham WH, Cowman AF, Schmidt CQ, Mertens HD, Liszewski MK, Hourcade DE, Barlow PN, Atkinson JP, (2014) Using mutagenesis and structural biology to map the binding site for the Plasmodium falciparum merozoite protein PfRh4 on the human immune adherence receptor. J Biol Chem 289: 450-463
81. Pechtl IC, Kavanagh D, McIntosh N, Harris CL, Barlow PN, (2011) Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem 286: 11082-11090
82. Persson BD, Schmitz NB, Santiago C, Zocher G, Larvie M, Scheu U, Casasnovas JM, Stehle T, (2010) Structure of the extracellular portion of CD46 provides insights into its interactions with complement proteins and pathogens. PLoS Pathog 6: e1001122
83. Reeves PJ, Callewaert N, Contreras R, Khorana HG, (2002) Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci USA 99: 13419-13424
84. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH, (2003) Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 100: 12966-12971
85. Ricklin D, Hajishengallis G, Yang K, Lambris JD, (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797
86. Ricklin D, Lambris JD, (2013a) Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 190: 3831-3838
87. Ricklin D, Lambris JD, (2013b) Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 190: 3839-3847
88. Riley RC, Tannenbaum PL, Abbott DH, Atkinson JP, (2002) Cutting edge: inhibiting measles virus infection but promoting reproduction: an explanation for splicing and tissue-specific expression of CD46. J Immunol 169: 5405-5409
89. Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ, (2014) New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 34: e00146
90. Rooijakkers SH, Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A, Ricklin D, Lambris JD, Janssen BJ, van Strijp JA, Gros P, (2009) Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol 10: 721-727
91. Rosengard AM, Liu Y, Nie Z, Jimenez R, (2002) Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc Natl Acad Sci USA 99: 8808-8813
92. Roversi P, Johnson S, Caesar JJ, McLean F, Leath KJ, Tsiftsoglou SA, Morgan BP, Harris CL, Sim RB, Lea SM, (2011) Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci USA 108: 12839-12844
93. Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, Lambris JD, (2013) Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol 190: 5712-5721
94. Schmidt CQ, Kennedy AT, Tham WH, (2015) More than just immune evasion: Hijacking complement by Plasmodium falciparum. Mol Immunol 67: 71-84
95. Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S, Smith RJ, Noris M, Goodship T, Atkinson JP, Fremeaux-Bacchi V, (2015) Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood 125: 2359-2369
96. Sfyroera G, Katragadda M, Morikis D, Isaacs SN, Lambris JD, (2005) Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol 174: 2143-2151
97. Sjoberg AP, Trouw LA, Blom AM, (2009) Complement activation and inhibition: a delicate balance. Trends Immunol 30: 83-90
98. Smith BO, Mallin RL, Krych-Goldberg M, Wang X, Hauhart RE, Bromek K, Uhrin D, Atkinson JP, Barlow PN, (2002) Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell 108: 769-780
99. Thomas BN, Donvito B, Cockburn I, Fandeur T, Rowe JA, Cohen JH, Moulds JM, (2005) A complement receptor-1 polymorphism with high frequency in malaria endemic regions of Asia but not Africa. Genes Immun 6: 31-36
100. Till M, Robson A, Byrne MJ, Nair AV, Kolek SA, Shaw Stewart PD, Race PR, (2013) Improving the success rate of protein crystallization by random microseed matrix screening. J Vis Exp 78: 50548
101. Tortajada A, Montes T, Martinez-Barricarte R, Morgan BP, Harris CL, de Cordoba SR, (2009) The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet 18: 3452-3461
102. Uhrinova S, Lin F, Ball G, Bromek K, Uhrin D, Medof ME, Barlow PN, (2003) Solution structure of a functionally active fragment of decay-accelerating factor. Proc Natl Acad Sci USA 100: 4718-4723
103. Weisman HF, Bartow T, Leppo MK, Boyle MP, Marsh HC Jr, Carson GR, Roux KH, Weisfeldt ML, Fearon DT, (1990) Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians 103: 64-72
104. Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ, McCallum SA, Embuscado L, DeForge L, Hass PE, van Lookeren Campagne M, (2006) Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444: 217-220
105. Williams P, Chaudhry Y, Goodfellow IG, Billington J, Powell R, Spiller OB, Evans DJ, Lea S, (2003) Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A. J Biol Chem 278: 10691-10696
106. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P, (2009) Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 10: 728-733
107. Yadav VN, Pyaram K, Mullick J, Sahu A, (2008) Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation. J Virol 82: 3283-3294
108. Zipfel PF, Hallstrom T, Riesbeck K, (2013) Human complement control and complement evasion by pathogenic microbes-tipping the balance. Mol Immunol 56: 152-160
109. Zipfel PF, Skerka C, (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9: 729-740